MD
MDBIF.US Medibio Limited
- Market cap
- USD 3.35M
- P/E
- -
- P/B
- 0.31x
- ROE
- -54.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MDBIF.US undervalued?
Graham numberThe Graham number of Medibio Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medibio Limited fundamental analysis
No fundamental analysis for Medibio Limited yet.
Medibio Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medibio Limited
TrivarX Limited, a biotechnology company, engages in the development of AI-driven, and scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. It is also involved in research, development, and commercialisation of diagnostic and pharmaceutical products. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is b…
Full company profileMedibio Limited financial statements
Medibio Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.1K | 205K | 365K | 134K | 1.26M | 1.01M | 960K | 889K | 1.13M | - |
| Gross Profit | -1.70M | 129K | 139K | -71.2K | 1.09M | 1.00M | -1.15M | -93.1K | 1.13M | -6.46M |
| Operating Income | -8.01M | -16.3M | -6.57M | -3.84M | 27.2K | -504K | 18.1K | -2.12M | 128K | -8.41M |
| EBITDA | -7.79M | -15.0M | -6.57M | -3.70M | -1.28M | -2.31M | -2.52M | -1.13M | -857K | -1.95M |
| Net Income | -8.27M | -16.3M | -6.59M | -3.87M | -1.49M | -12.7M | -3.07M | -1.24M | -943K | -8.75M |
| EPS | -0.07 | -0.08 | -0.59 | -0.09 | -0.02 | -0.12 | -0.02 | 0.00 | 0.00 | -0.95 |
| Balance Sheet | ||||||||||
| Total Assets | 19.3M | 19.1M | 13.3M | 14.0M | 17.4M | 8.49M | 8.03M | 11.1M | 13.5M | 16.5M |
| Total Liabilities | 5.94M | 5.08M | 4.70M | 1.40M | 964K | 1.38M | 1.69M | 1.17M | 831K | 565K |
| Shareholders' Equity | 13.3M | 14.0M | 8.60M | 12.6M | 16.4M | 7.11M | 6.34M | 9.89M | 12.7M | 15.9M |
| Cash & Short-term Investments | 5.01M | 6.12M | 1.33M | 813K | 2.31M | 1.03M | 214K | 848K | 1.25M | 2.44M |
| Total Debt | 133K | 120K | 2.75M | 76.9K | 24.8K | 66.4K | 110K | 16.0K | 169K | 128K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.42M | -12.2M | -6.80M | -3.58M | -1.70M | -1.66M | -932K | -1.48M | -162K | -1.50M |
| Capital Expenditure | 0.00 | 0.00 | 1.14M | 1.54M | 1.83M | 3.11M | 2.26M | 2.50M | 1.00 | 1.50M |
| Free Cash Flow | -5.42M | -12.2M | -7.94M | -5.12M | -3.53M | -4.77M | -3.19M | -3.35M | -162K | -2.67M |
| Ratios | ||||||||||
| ROE | -62.1% | -116.5% | -76.6% | -30.7% | -9.1% | -178.9% | -48.4% | -12.5% | -7.5% | -54.9% |
| ROA | -43.0% | -85.5% | -49.5% | -27.6% | -8.6% | -149.8% | -38.2% | -11.2% | -7.0% | -53.0% |
| Net Profit Margin | -35,812.0% | -7,956.1% | -1,806.5% | -2,900.7% | -117.7% | -1,264.7% | -319.7% | -139.2% | -83.5% | - |
| Debt to Equity | 0.01x | 0.01x | 0.32x | 0.01x | 0.00x | 0.01x | 0.02x | 0.00x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medibio Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 2.34M | 0.21 | - |
| 2018 | - | - | - |
| 2017 | AUD 1.20M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 24, 2023.
Who owns Medibio Limited
- Insiders 25.33%
- Institutions 6.76%
- Public & others 67.91%
- Shares outstanding 1.15B
- Free float 725M
Medibio Limited company profile
- Company name
- Medibio Limited
- Ticker
- MDBIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- June
- Address
- Suite 1.01, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 3 8319 0962
- Website
- trivarx.com
About Medibio Limited
TrivarX Limited, a biotechnology company, engages in the development of AI-driven, and scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. It is also involved in research, development, and commercialisation of diagnostic and pharmaceutical products. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Hawthorn East, Australia.
Medibio Limited management
7- Dr. Danielle Meyrick M.D., Ph.D.Chief Executive Officer
- Mr. Kai SunChief Operating Officer
- Dr. Anthony James KeatingExecutive Director
- Mr. Josh PurdyPublic Relations Director
- Mr. Massimiliano GrassiHead of Artificial Intelligence
- Mr. Cameron Peter Jones C.A.Joint Company Secretary
- Ms. Nova Anne TaylorJoint Company Secretary